[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
IJRR Information::
For Authors::
For Reviewers::
Subscription::
News & Events::
Web Mail::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
ISSN
Hard Copy 2322-3243
Online 2345-4229
..
Online Submission
Now you can send your articles to IJRR office using the article submission system.
..

AWT IMAGE

AWT IMAGE

:: ::
Back to the articles list Back to browse issues page
Treatment of high-altitude polycythemia with radiopharmaceutical platform of poly (lactic-co-glycolic acid) nanoparticles loaded with hydroxyurea
J. Nie , D. Wang , M.J. Li
School of Ethnic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China , fcmlnj@163.com
Abstract:   (16 Views)
Background: High Altitude Polycythemia (HAPC) is a chronic hypoxia-related disorder characterized by excessive erythrocytosis, hypercoagulability, and organ dysfunction. Hydroxyurea (HU) is used clinically but is limited by systemic toxicity and suboptimal targeting. This study aimed to evaluate the therapeutic efficacy and biodistribution of a radiopharmaceutical platform based on poly(lactic-co-glycolic acid) nanoparticles loaded with hydroxyurea (HU-PLGA-NPs) in an experimental HAPC model. Materials and Methods: Sixty male Sprague–Dawley rats with hypobaric hypoxia-induced HAPC were randomized into three groups: HU-PLGA-NPs, conventional HU, and supportive treatment. Nanoparticles were radiolabeled with technetium-99m to assess in vivo biodistribution using SPECT/CT imaging. Hematological parameters, coagulation indices, hemorheology, immune markers, bone marrow apoptosis, and liver and renal function were evaluated over 12 weeks. Results: HU-PLGA-NP treatment significantly reduced hemoglobin, hematocrit, blood viscosity, and coagulation abnormalities compared with conventional HU and supportive therapy (p<0.05). Imaging and biodistribution studies demonstrated preferential accumulation in bone marrow and spleen. Improved immune parameters and reduced hepatic and renal toxicity were observed in the nanoparticle group. Conclusions: The HU-PLGA-NP radiopharmaceutical platform enhances therapeutic efficacy and targeting while reducing systemic toxicity in HAPC, representing a promising strategy for precision treatment.
Keywords: Hydroxyurea, PLGA nanoparticles, radiopharmaceutical platform, technetium-99m, high altitude polycythemia, biodistribution, liver function, coagulation indices.
Full-Text [PDF 1117 kb]   (3 Downloads)    
Type of Study: Original Research | Subject: Radiation Biology
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA



XML     Print



Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Back to the articles list Back to browse issues page
International Journal of Radiation Research
Persian site map - English site map - Created in 0.13 seconds with 50 queries by YEKTAWEB 4741